Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor. 

Read More